Key facts
- This page summarizes Cooper C. Collins's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Feb 2025, 21:08.
Cooper C. Collins - 18 Feb 2025 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)
- Reporting relationship
- Director
- Issuer ticker
- TXMD
- Reported as of
- 18 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2025, 21:08:04 UTC
- Prior SEC filing
- 26 Aug 2024
- Next SEC filing
- 05 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cooper C. Collins
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cooper C. Collins filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 20 Feb 2025.
Change
- Previous filing in this sequence was filed on 26 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXMD
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +8,500
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 60,516
- Date
- 18 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TXMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -8,500
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 18 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,500
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024.